DEF 14A: ALT5 Sigma Corporation Announces 2024 Annual Meeting of Stockholders

ALT5 Sigma Corporation will hold its 2024 Annual Meeting of Stockholders on December 18, 2024, to vote on key proposals including the election of directors, approval of an equity incentive plan, and ratification of the appointment of the independent auditor.

Summary

• ALT5 Sigma Corporation will hold its 2024 Annual Meeting of Stockholders on December 18, 2024.
• Stockholders will vote on the election of six directors, the approval of the 2024 Equity Incentive Plan, and the ratification of the issuance of 150,000 shares of common stock to the Company President.
• They will also vote to ratify the appointment of Hudgens CPA, PLLC as the independent registered public accounting firm for fiscal year 2024 and to approve a proposal to adjourn the Annual Meeting if necessary.
• The record date for determining stockholders eligible to vote is October 21, 2024.
• The Board of Directors recommends voting FOR all proposals.
• The company has three outstanding classes or series of voting stock entitled to vote at the Annual Meeting, Common Stock, Series A-1 Preferred Stock, and Series S Preferred Stock.
• Each outstanding share of Common Stock entitles its holder to cast one vote on each matter to be voted upon.
• Each outstanding share of Series A-1 Preferred Stock entitles its holder to cast 17 votes per share on each matter to be voted upon.
• Each outstanding share of Series S Preferred Stock entitles its holder to cast one vote per share on each matter to be voted upon.
• The holders of outstanding Common Stock are entitled to a total of 14,019,015 votes.
• The holders of Series A-1 Preferred Stock are entitled to a total of 399,151 votes.
• The holders of Series S Preferred Stock are entitled to a total of 100,000 votes.

Sentiment

Score: 7

Explanation: The document is neutral in tone, providing factual information about the upcoming annual meeting and proposals. The board recommends voting for all proposals, suggesting a positive outlook from management's perspective.

Positives

• The Board of Directors is actively seeking stockholder input on key decisions.
• The proposed 2024 Equity Incentive Plan aims to align executive compensation with stockholder value.
• The company is addressing a prior grant of shares to the president that did not have sufficient shares available under the 2023 Equity Incentive Plan.
• The company is seeking to ratify the appointment of an independent auditor.

Negatives

• The company did not have sufficient shares available under its 2023 Equity Incentive Plan to complete the grant of shares to its President on August 19, 2024.

Risks

• Failure to approve the proposals could impact the company's ability to attract and retain key personnel.
• The company's strategic plan to separate into two distinct companies could face challenges.
• The company's reliance on related party transactions could pose a conflict of interest.

Future Outlook

The company recently announced its strategic plan to separate into two distinct companies – fintech and biotechnology, with ALT5 continuing as a leading fintech organization post-separation and the Biotech segment emerging as Alyea Therapeutics Corporation.

Management Comments

• Peter Tassiopoulos has successfully completed over $1 billion in M&A, divestitures, and financing transactions throughout his career.
• Tony Isaacs specialty is negotiation and problem-solving of complex real estate and business transactions.
• Mr. Johnsons more than 30 years of experience is primarily in the areas of process improvement, complex debt financings, SEC and financial reporting, turn-arounds, corporate restructuring, global finance, merger and acquisitions and returning companies to profitability and enhancing stockholder value.

Industry Context

The company's strategic plan to separate into two distinct companies – fintech and biotechnology reflects a trend of companies focusing on core competencies and unlocking value through spin-offs.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• However, the company's executive compensation practices can be compared to those of other small-cap companies in the fintech and biotechnology sectors.
• The company's audit fees can be compared to those of other companies of similar size and complexity.

Management Changes

Related Party Transactions

• Tony Isaac, the Company's President, is the father of Jon Isaac, President and Chief Executive Officer of Live Ventures Incorporated ( Live Ventures ) and managing member of ICG.
• Tony Isaac, Chief Executive Officer and Richard Butler, Board of Directors member of the Company, are both Board of Directors members of Live Ventures.
• The Company also shares certain executive, accounting and legal services with Live Ventures.
• The principal of VM7 is Virland A. Johnson, our Chief Financial Officer.
• ICG is a record and beneficial owner of 13.6% of the outstanding common stock of the Company.

Stakeholder Impact

• Approval of the proposals could impact the company's ability to attract and retain key personnel, which could affect the company's performance and stock price.
• The company's strategic plan to separate into two distinct companies could create new opportunities for both the fintech and biotechnology businesses.
• The outcome of the vote on the ratification of the appointment of the independent auditor could affect the company's financial reporting and transparency.

Next Steps

• Stockholders are urged to vote on the proposals outlined in the Proxy Statement.
• The company will hold its Annual Meeting of Stockholders on December 18, 2024.
• The company will continue to execute its strategic plan to separate into two distinct companies.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Stockholders, Directors, Equity Incentive Plan, Auditor, ALT5 Sigma, Governance